药品招标采购评审分组的比较和改进  

Comparison and Improvement on Review Grouping of Drug Purchasing by Invitation to Bid

作　　者：杨勇[1] 田侃[1] 徐爱军[1] 

机构地区：[1]南京中医药大学,南京210046

出　　处：《中国药事》2013年第12期1246-1249,共4页Chinese Pharmaceutical Affairs

摘　　要：目的为完善新一轮药品招标采购工作提供参考。方法通过文献检索,比较当前国内部分省份药品集中招标采购中评审分组的规则,分析评审分组或质量层次划分的异同点,总结划分依据和实施效果。结果与结论明确分组规则的不足,提出了优化招标采购评审分组规则的建议。Objective To provide the reference for perfecting a new round of drug bidding procurement work.Methods By searching literature,the drug centralized bid procurement rules of the review grouping in some provinces in China were compared,the similarities and differences of different layers of review grouping or quality were analyzed,the division basis and implementation effect were summarized.Results and Conclusion The advantages and disadvantages of grouping rules were defined,and the measures and suggestions for the optimization of bidding procurement review grouping rules were put forward.

关 键 词：药品招标 药品集中招标采购 评审分组 

分 类 号：R95[医药卫生—药学]